Most of the hosts used to produce the 151 recombinant pharmaceuticals so far approved for
human use by the Food and Drug Administration (FDA) and/or by the European Medicines …

Diabetes, growth or clotting disorders are among the spectrum of human diseases related to
protein absence or malfunction. Since these pathologies cannot be yet regularly treated by …

Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early
1980s, the amount of recombinant pharmaceutical proteins obtained by microbial …

Escherichia coli has been the pioneering host for recombinant protein production, since the
original recombinant DNA procedures were developed using its genetic material and …

Both conventional and innovative biomedical approaches require cost-effective protein
drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and …

Almost all of the 200 or so approved biopharmaceuticals have been produced in one of
three host systems: the bacterium Escherichia coli, yeasts (Saccharomyces cerevisiae …

Different hosts have been used for recombinant protein production, ranging from simple
bacteria, such as Escherichia coli and Bacillus subtilis, to more advanced eukaryotes as …

Since the manufacture of the first biotech product for a fledgling biopharmaceutical industry
in 1982, Escherichia coli, has played an important role in the industrial production of …

In recent years, the production of recombinant pharmaceutical proteins in heterologous
systems has increased significantly. Most applications involve complex proteins and …

Microbial enzymes have been used in a large number of fields, such as chemical,
agricultural and biopharmaceutical industries. The enzyme production rate and yield are the …